According to ADMA Biologics 's latest financial reports the company's current revenue (TTM) is $0.25 B. In 2022 the company made a revenue of $0.15 B an increase over the years 2021 revenue that were of $80.94 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.25 B | 67.59% |
2022 | $0.15 B | 90.36% |
2021 | $80.94 M | 91.72% |
2020 | $42.21 M | 43.85% |
2019 | $29.34 M | 72.79% |
2018 | $16.98 M | -25.37% |
2017 | $22.76 M | 113.49% |
2016 | $10.66 M | 48.53% |
2015 | $7.17 M | 21.34% |
2014 | $5.91 M | 92.84% |
2013 | $3.06 M | 174.35% |
2012 | $1.11 M | |
2011 | N/A | |
2010 | N/A |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Repligen
RGEN | $0.63 B | 147.38% | ๐บ๐ธ USA |
Novavax NVAX | $0.69 B | 168.56% | ๐บ๐ธ USA |
Cel-Sci
CVM | N/A | N/A | ๐บ๐ธ USA |